

CLAIMS

We claim:

1. A method for administering a lipopeptide antibiotic, comprising the step of administering to a patient in need thereof a therapeutically effective amount of the lipopeptide antibiotic at a dosage interval that does not result in muscle toxicity.

2. The method according to claim 1, wherein the lipopeptide antibiotic is administered once every 24 hours to once weekly.

3. The method according to claim 2, wherein the lipopeptide antibiotic is administered once every 24 hours, 48 hours, 72 hours or 96 hours.

4. The method according to claim 1, wherein the lipopeptide antibiotic is selected from the group consisting of daptomycin, a daptomycin derivative, A54145 and a A54145 derivative.

5. The method according to claim 4, wherein the lipopeptide antibiotic is daptomycin.

6. A method for administering daptomycin, comprising the step of administering to a patient in need thereof a therapeutically effective amount of daptomycin in a dose of 3 to 75 mg/kg of daptomycin, wherein the daptomycin is administered once every 24 hours to once weekly.

7. The method according to claim 6, wherein the dose is 3 to 12 mg/kg.

10082544-022002

SUB  
B3/5

10  
SUB  
B3/

SUB  
B4/

8. The method according to claim 7, wherein the dose is 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg/kg.

SUB  
85

9. The method according to claim 6, wherein the dose is 10 to 25

mg/kg.

5

10. The method according to claim 9, wherein the dose is 10, 11, 12, 13, 14, 15, 16, 20 or 25 mg/kg.

SUB  
36

11. The method according to either of claim 1 or claim 6, wherein an antibiotic other than a lipopeptide antibiotic is co-administered with the lipopeptide antibiotic.

10

12. The method according to claim 11 wherein said lipopeptide antibiotic is daptomycin.

13. The method according to claim 11, wherein said antibiotic is selected from the group consisting of penicillins and related drugs, carbapenems, cephalosporins and related drugs, aminoglycosides, bacitracin, gramicidin, mupirocin, chloramphenicol, thiamphenicol, fusidate sodium, lincomycin, clindamycin, macrolides, novobiocin, polymyxins, rifamycins, spectinomycin, tetracyclines, vancomycin, teicoplanin, streptogramins, anti-folate agents, sulfonamides, trimethoprim and its combinations, pyrimethamine, synthetic antibacterials, nitrofurans, methenamine mandelate, methenamine hippurate, nitroimidazoles, quinolones, fluoroquinolones, isoniazid, ethambutol, pyrazinamide, para-aminosalicylic acid (PAS), cycloserine, capreomycin, ethionamide, prothionamide, thiacetazone and viomycin.

14. The method according to claim 11, wherein said antibiotic is selected from the group consisting of imipenen, amikacin, netilmicin, fosfomycin, gentamicin and teicoplanin.

15. The method according to claim 11, wherein said administering is via oral, subcutaneous or intravenous administration.

16. A method for administering daptomycin, comprising the step of administering to a patient or animal in need thereof a therapeutically effective amount of daptomycin at a dose of 3 to 75 mg/kg of daptomycin, wherein daptomycin is administered once every 24 hours.

17. The method according to claim 16, wherein the dose is 3 to 12 mg/kg.

18. The method according to claim 17, wherein the dose is 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg/kg.

19. The method according to claim 16, wherein the dose is 10 to 25 mg/kg.

20. The method according to claim 19, wherein the dose is 10, 11, 12, 13, 14, 15, 16, 20 or 25 mg/kg.

21. The method according to claim 17, wherein the dose is 25 to 75 mg/kg.

22. The method according to claim 21, wherein the dose is 25, 50 or 75 mg/kg.

10082544-022002

23. The method according to claim 16, wherein said method reduces muscle toxicity compared to administration of daptomycin at a more frequent interval than 24 hours.

24. The method according to claim 18, wherein the dose is 4 mg/kg administered once every 24 hours.

25. The method according to claim 18, wherein the dose is 6 mg/kg administered once every 24 hours.

26. The method according to any one of claims 1, 6 or 16, wherein said administering is via oral, subcutaneous or intravenous administration.

27. A method for administering quinupristin/dalfopristin, comprising the step of administering to a patient in need thereof a therapeutically effective amount of quinupristin/dalfopristin at a dosage interval that does not result in muscle toxicity.

28. The method according to claim 27, wherein quinupristin/dalfopristin is administered once every 24 hours to once weekly.

29. The method according to claim 28, wherein quinupristin/dalfopristin is administered once every 24 hours, 48 hours, 72 hours or 96 hours.

30. The method according to claim 27, wherein said quinupristin/dalfopristin is administered at a dose of 7.5 to 30 mg/kg.

200220-44528001

Qulb  
A2

31. The method according to claim 27, wherein said quinupristin/dalfopristin is administered at a dose of 7.5, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 or 30 mg/kg.

5 32. A pharmaceutical composition comprising a single dose of daptomycin and a pharmaceutically acceptable carrier, wherein said single dose is 7 to 15 mg/kg.

33. A pharmaceutical composition comprising a single dose of quinupristin/dalfopristin and a pharmaceutically acceptable carrier, wherein said  
10 single dose is 10 to 30 mg/kg.

10082544.022002